Last reviewed · How we verify
Optimal Medical Therapy (OMT)
Optimal Medical Therapy (OMT) is a comprehensive, guideline-based treatment approach that combines multiple pharmacological and lifestyle interventions tailored to individual patient characteristics.
Optimal Medical Therapy (OMT) is a comprehensive, guideline-based treatment approach that combines multiple pharmacological and lifestyle interventions tailored to individual patient characteristics. Used for Coronary artery disease management (as a treatment protocol comparator), Heart failure management (as a treatment protocol comparator).
At a glance
| Generic name | Optimal Medical Therapy (OMT) |
|---|---|
| Sponsor | Charite University, Berlin, Germany |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
OMT is not a single drug entity but rather a standardized clinical protocol that typically includes evidence-based medications (such as beta-blockers, ACE inhibitors, statins, and antiplatelet agents) combined with lifestyle modifications. It is designed to optimize outcomes by individualizing therapy based on patient-specific factors, comorbidities, and disease severity. OMT serves as a control or comparator arm in clinical trials rather than an investigational therapeutic agent.
Approved indications
- Coronary artery disease management (as a treatment protocol comparator)
- Heart failure management (as a treatment protocol comparator)
Common side effects
Key clinical trials
- CANF-Comb-II PET-MR in Atherosclerosis Multisite
- Pivotal Trial to Evaluate TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (The TRINITY Pivotal Trial) (NA)
- AGECTO Study: PCI vs. Optimal Medical Therapy for CTO in the Octogenarian Patients
- TRISCEND II Pivotal Trial (NA)
- Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation (NA)
- Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy (NA)
- Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial (NA)
- TRICuspid Intervention in Heart Failure Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optimal Medical Therapy (OMT) CI brief — competitive landscape report
- Optimal Medical Therapy (OMT) updates RSS · CI watch RSS
- Charite University, Berlin, Germany portfolio CI